BWXT Awarded Phase Two of Microreactor Evaluation Contract for State of Wyoming
(LYNCHBURG, Va. – June 17, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced the award of the second phase of a contract with the Wyoming Energy Authority to assess the viability of deploying small-scale nuclear reactors in the state as a source of resilient and reliable energy to augment existing power generation resources.
BWXT-led Team Awarded $30 Billion Management and Operating Contract for National Nuclear Security Administration’s Pantex Plant
(LYNCHBURG, Va. – June 14, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced a contract award from the U.S. Department of Energy, National Nuclear Security Administration (DOE/NNSA) for management and operations of the Pantex Plant. Following an initial term of five years, NNSA has the ability to award three additional five-year option periods. If all contract options are exercised, the contract will span 20 years at a funding level of approximately $30 billion.
BWXT Medical Submits Drug Master File for Actinium-225 API to U.S. Food and Drug Administration
BWXT Medical Ltd. has submitted a Drug Master File (DMF) to the U.S. Drug and Food Administration (FDA) for No Carrier Added (n.c.a.) Actinium-225 (Ac-225) Active Pharmaceutical Ingredient.